Post-approval packaging, bulk testing of OTCs through FDA SUPAC-IR sought by NDMA.
• By The Tan Sheet
POST-APPROVAL CHANGES IN OTC PACKAGING AND BULK TESTS THROUGH SUPAC sought by the Nonprescription Drug Manufacturers Association. Speaking at the group's annual Manufacturing Controls Seminar in Philadelphia Oct. 10-11, Manufacturing Controls Committee Chair Donald Cadge said: "It seems reasonable" that after providing and proving equivalency through FDA's Scale-Up and Post-Approval Changes guidance for immediate-release products, "it stands to reason that a company should also be able to keep all production in place but move the packaging and/or the testing of that bulk after proving equivalency." Cadge is with McNeil Consumer Products.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
Pfizer told the Pink Sheet it would work with the health technology assessment institute, NICE, with the hope of making Hympavzi available to patients with hemophilia A via the National Health Service.
The verdict by the Unified Patent Court in the dispute between Sanofi/Regeneron Pharmaceuticals and Amgen explains what companies should look out for when deciding whether infringement has taken place when it comes to second medical use patents.